What GHK-Cu Compound Is
A reading of the copper-tripeptide literature as a single diagram — and a plain account of what it is and is not.
What GHK-Cu Compound is
GHK-Cu Compound is a reading of the published copper-tripeptide science: it publishes summaries of the peer-reviewed research literature on GHK-Cu, the copper tripeptide. It runs no clinic and keeps no clinical staff; it gives no medical advice and recommends no dose; and it makes, stocks, and sells nothing. Its work is to read the record and diagram it faithfully.
The site exists because the published record on GHK-Cu is unusually composable — one small copper-binding peptide whose reported activity partitions cleanly into a handful of research domains: skin and collagen, hair-follicle, wound-healing and angiogenesis, gene-expression, antioxidant chemistry, and safety. We read that record the way a diagram reads a whole: each domain is a segment, the headline proportions live in the center, and every slice ties back to a study. The aim is that a reader can see where the copper signal lands and how much, while the prose holds the honest detail underneath.
What "Compound" means here
The word "Compound" in the name is chemical-substance framing, not a claim about services. GHK-Cu is, literally, a compound — a tripeptide chelated to a copper(II) ion — and the name signals the neutral, composition-of-a-whole register this digest takes. No treatment, consultation, or prescription is offered here, and nothing resembling a pharmacy, a telehealth service, or a storefront sits behind the page. A modifier that sounds clinical is editorial framing about a position relative to the literature, never a healthcare service offered here.
How we handle the evidence
Every quantitative claim on this site — every concentration, percentage, hair count, gene-modulation figure, and molecular constant — maps to a numbered citation drawn from the peer-reviewed literature, listed on the references page with DOIs and PubMed identifiers. We distinguish carefully between the free GHK peptide and the copper-bound GHK-Cu complex, because most documented activity is copper-dependent and the two are routinely conflated elsewhere [7]. We are equally explicit about the gaps: much of the gene-expression literature traces to a single investigator and his colleagues and awaits independent protein-level validation, and there is no validated human pharmacokinetic data for systemic GHK-Cu [2][3]. Where a study tested an analog rather than GHK-Cu, we say so. The goal is a record a reader can trust precisely because its limits are stated as clearly as its findings.